They all sounded a bit more anxious than usual, but that can be because of the new CEO. I did take that the CEO said he will meet with everyone, I understood that to say ARRY will be going around making the rounds with all the institutional investors.
4. Koch confirmed that we will have top-line Phase 2 data for selumetinib against BRAF melanoma this quarter (I was unsure by the vague wording in the quarterly results PR.)
Market Data 
Markets 
AI
